SAN LUIS OBISPO, California, November 2nd 2015. FzioMed, Inc., which recently celebrated 19 years in the medical device business, has received a new patent, US 9,161,987 B2, for crosslinked compositions of carboxymethylcellulose (CMC) and polyethylene glycol (PEG) for medical uses. The crosslinking technology provides devices that can be made with a variety of viscoelastic properties, to provide space filling and load bearing materials such as nucleus pulposus replacements. Additionally, the CMC/PEG crosslinked compositions can be used as anti-adhesion devices, drug delivery vehicles, and medical devices for lubrication of tissues.
“This patent opens up new horizons for our technology, particularly in our core spine business and will enable us to explore new applications for our unique combination of polymers,” said John Krelle, President and CEO of FzioMed.
“Our Oxiplex® spinal platform is very important to us and this new patent allows us to expand our horizon to develop products that can provide structural support, allowing patients to return to a life of pain free mobility.”
FzioMed brands include: Dynavisc® to reduce fibrosis in tendon and peripheral nerve surgery; Oxiplex®/AP for use in gynecologic procedures; and Laresse®, a dermal filler for the correction of facial lines and folds.
About FzioMed
FzioMed, Inc. is a privately held medical device company that develops, manufactures and markets absorbable surgical biomaterials based on its patented scientific technology. For more information, please visit www.fziomed.com
FzioMed®, Oxiplex®, Oxiplex®/AP, Laresse®, and Dynavisc® are registered trademarks of FzioMed, Inc.